AbbVie (ABBV): Q1 2026 Earnings in Focus After -8% YTD Decline
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $14.8 billion, reflecting about 11% year-over-year growth driven by immunology drugs.
- Consensus adjusted EPS estimate stands at $2.69, though AbbVie recently guided $2.56–$2.60 after a $744 million IPR&D (intellectual property research and development) charge.
- Skyrizi sales projected at $4.43 billion and Rinvoq at $2.07 billion, key to offsetting Humira's ongoing decline.
- Investors watching for updates on 2026 full-year guidance of $13.96–$14.16 adjusted EPS.
- AbbVie's immunology portfolio remains central amid post-Humira transition.
- Stock trades down about 8% year-to-date, heightening focus on execution.
Earnings Context and Why It Matters
As AbbVie (ABBV) prepares to report Q1 2026 earnings on April 29, this feels like a key milestone in the company's shift away from Humira dominance toward growth from newer immunology drugs like Skyrizi and Rinvoq. With Humira facing biosimilar competition since 2023, AbbVie still delivered record 2025 revenue of $61.2 billion, fueled by more than 32% growth in those star products. From what I see, this report will help investors assess whether the immunology momentum holds up against patent expirations, R&D spending, and competition in a market exceeding $200 billion. Solid numbers here could reinforce AbbVie's position as a dividend aristocrat with a promising pipeline, while any misses could add to volatility in the sector.
Earnings Expectations
Wall Street looks for Q1 2026 net revenue of $14.72–$14.78 billion, up about 11% from Q1 2025, according to Zacks and MarketBeat consensus figures. Adjusted diluted EPS consensus sits at $2.67–$2.70, following the Q4 2025 beat of $2.71. That said, AbbVie recently adjusted its Q1 guidance downward to $2.56–$2.60 due to a $744 million IPR&D charge from acquisitions.
In the immunology segment, expectations center on Skyrizi at $4.43 billion (up ~45% YoY) and Rinvoq at $2.07 billion (up ~60% YoY), based on Zacks estimates, as they work to counter Humira's U.S. decline. I'm paying close attention to operational growth, margin performance, and any pipeline updates in oncology and neuroscience. AbbVie has beaten EPS estimates in the past four quarters, though the stock's response has depended heavily on guidance.
Market Reaction and Investor Sentiment
Heading into earnings, sentiment leans cautiously optimistic, even with the stock down 8% year-to-date amid broader biotech pressures and the recent guidance tweak. Options pricing suggests about 7% volatility after the report. On the bullish side, the immunology portfolio's run-rate now tops $7 billion per quarter; bears, however, point to IPR&D impacts and Humira erosion risks. Looking back, beats with positive guidance have driven +2–5% gains, but margin pressures have led to downside.
Tools I Use: Tickeron’s AI Screener
One resource I turn to regularly in my analysis is Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of names using technical patterns, fundamentals, trends, volatility, and AI signals—customizing by industry, market cap, indicators, price patterns, and performance metrics. In reviewing ABBV, for instance, it helped me quickly spot how it compares to peers on key trends. This streamlines my workflow far beyond manual screening, surfacing trade ideas, breakouts, and opportunities efficiently.
Forward Outlook and Key Factors to Monitor
After Q1 results, the spotlight will turn to whether AbbVie reaffirms or adjusts its full-year 2026 guidance of $13.96–$14.16 adjusted EPS, pointing to ~4–5% growth. If Skyrizi and Rinvoq keep accelerating in psoriasis, Crohn's disease, and emerging indications, revenue could approach the $67 billion consensus.
Pipeline developments to watch include label expansions, Phase 3 readouts in immunology and oncology—like ABBV-383 for multiple myeloma—and M&A progress. I'll be tracking cost discipline with R&D at ~20% of sales and gross margins around 85%, plus international expansion to offset U.S. biosimilar headwinds. In my view, this is important because broader factors like Fed rate decisions, peer earnings from Eli Lilly and Johnson & Johnson, and election-year drug pricing policies could influence the path ahead. Strong execution positions AbbVie for dividend increases and portfolio stability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for ABBV turns positive, indicating new upward trend
ABBV saw its Momentum Indicator move above the 0 level on September 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 52 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on September 16, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 28 of 46 cases over the following month. The odds of a continued upward trend are 61%.
ABBV moved above its 50-day moving average on September 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 218 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 22 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 49%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.050). ABBV has a moderately high P/E Ratio (74.565) as compared to the industry average of (34.258). Projected Growth (PEG Ratio) (0.540) is also within normal values, averaging (5.614). Dividend Yield (0.026) settles around the average of (0.025) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement